1. [CASE 1 — QUESTION 1] A 64-year-old man with a history of alcohol use disorder is admitted to the intensive care unit (ICU) following aspiration of gastric contents during a witnessed seizure. He is intubated for airway protection. On day 2, his chest radiograph shows bilateral infiltrates, his PaO2/FiO2 (ratio of partial pressure of arterial oxygen to fraction of inspired oxygen) is 82 mmHg on FiO2 (fraction of inspired oxygen) 0.80 with PEEP (positive end-expiratory pressure) 10 cmH2O, and his respiratory failure is not primarily attributable to cardiac failure. Onset was within 24 hours of his seizure. The ICU fellow wants to confirm the ARDS (acute respiratory distress syndrome) diagnosis and severity classification before planning escalation. Which of the following correctly classifies this patient's ARDS severity by the Berlin definition and identifies the specific threshold that places him in this category?

• A) The patient has mild ARDS by the Berlin definition, defined by a PaO2/FiO2 of 201 to 300 mmHg with at least 5 cmH2O PEEP; mild ARDS does not mandate neuromuscular blockade or prone positioning but does require lung-protective ventilation with low tidal volume
• B) The patient has severe ARDS by the Berlin definition, defined by a PaO2/FiO2 of 100 mmHg or below with at least 5 cmH2O PEEP; this severity category identifies patients at highest risk of death and is the threshold above which escalation to neuromuscular blockade, prone positioning, and inhaled rescue vasodilators is considered
• C) The patient has moderate ARDS by the Berlin definition, defined by a PaO2/FiO2 of 101 to 200 mmHg with at least 5 cmH2O PEEP; moderate ARDS mandates immediate initiation of extracorporeal membrane oxygenation (ECMO) as the only intervention shown to reduce mortality at this severity level
• D) The patient cannot be classified by the Berlin definition because alcohol-related aspiration is an exclusionary etiology — the Berlin definition applies only to ARDS from sepsis, pneumonia, and trauma; aspiration-related ARDS requires the older Murray Lung Injury Score classification
• E) The patient has severe ARDS, but the Berlin definition severity classification is based on the SpO2/FiO2 ratio rather than the PaO2/FiO2 ratio, and the thresholds differ from those used for the PaO2/FiO2 ratio by a factor that requires recalculation before escalation decisions are made

2. [CASE 1 — QUESTION 2] Continuing with the same patient. The team initiates lung-protective ventilation at tidal volume (Vt) 6 mL/kg ideal body weight (IBW) with PEEP 12 cmH2O. An inspiratory hold reveals a plateau airway pressure (Pplat) of 34 cmH2O. Arterial blood gas shows pH 7.28, PaCO2 (partial pressure of arterial carbon dioxide) 62 mmHg, and PaO2 72 mmHg. The respiratory therapist asks whether the Pplat is acceptable and, if not, what adjustment is indicated and what clinical consequence must be accepted. Which of the following correctly identifies the clinical problem, the required adjustment, and the physiological trade-off?

• A) A Pplat of 34 cmH2O is within the acceptable ARDSNet range of up to 40 cmH2O; no tidal volume adjustment is required at this Pplat, and the respiratory acidosis should be addressed by increasing the respiratory rate from its current setting to increase minute ventilation and normalize PaCO2
• B) A Pplat of 34 cmH2O indicates insufficient PEEP rather than excessive tidal volume; the correct adjustment is to increase PEEP by 4 cmH2O increments until Pplat falls below 30 cmH2O by recruiting collapsed alveoli and distributing pressure across a greater lung volume
• C) A Pplat of 34 cmH2O confirms that the patient has stiff chest wall compliance from abdominal distension, not true alveolar overdistension; the transpulmonary pressure is likely safe, and the appropriate response is esophageal manometry to measure pleural pressure before any tidal volume reduction
• D) A Pplat of 34 cmH2O exceeds the ARDSNet ceiling of 30 cmH2O, indicating alveolar overdistension in the aerated lung fraction; the tidal volume must be reduced in 1 mL/kg IBW increments to a minimum of 4 mL/kg IBW until Pplat reaches 30 cmH2O or below, and the team must accept further worsening of the existing respiratory acidosis as the necessary trade-off for preventing volutrauma
• E) A Pplat of 34 cmH2O is elevated, but tidal volume reduction is not indicated when PaCO2 is already elevated to 62 mmHg; further CO2 retention from tidal volume reduction in a patient with existing hypercapnia carries a seizure risk that outweighs the volutrauma benefit, and the team should maintain the current Vt and manage pressure with a prone positioning trial instead

3. [CASE 1 — QUESTION 3] Continuing with the same patient. After Vt reduction to 5 mL/kg IBW, Pplat is now 28 cmH2O. The patient remains at PaO2/FiO2 of 88 mmHg on FiO2 0.80 with PEEP 12 cmH2O — still meeting severe ARDS criteria on day 3. The team considers adding dexamethasone based on the DEXA-ARDS trial. The attending asks the resident to state the correct dose, duration, proposed mechanism, and the specific patient population in which the mortality benefit was demonstrated. Which of the following is correct?

• A) The DEXA-ARDS trial demonstrated mortality benefit with dexamethasone 20 mg IV daily for 5 days followed by 10 mg IV daily for 5 days in patients with moderate-to-severe ARDS (PaO2/FiO2 at or below 200 mmHg on optimized ventilator settings), reducing 60-day mortality from 36.4 percent to 21.1 percent; the proposed mechanism is suppression of the sustained inflammatory phase that perpetuates ongoing lung injury beyond the initial insult
• B) The DEXA-ARDS trial demonstrated mortality benefit with dexamethasone 6 mg IV daily for 10 days in patients with any-severity ARDS (PaO2/FiO2 below 300 mmHg); this dose was selected because it matches the dexamethasone dose used in the RECOVERY trial for COVID-19 and produces equivalent anti-inflammatory suppression with lower hypothalamic-pituitary-adrenal axis suppression than the 20 mg dose
• C) The DEXA-ARDS trial demonstrated that corticosteroid benefit in ARDS is greatest when initiated in the fibroproliferative phase (day 7 to 14 of illness) rather than the early exudative phase, because glucocorticoids specifically suppress TGF-beta-driven fibroblast activation and collagen deposition that predominates after the first week — early initiation in the exudative phase is not supported by the trial
• D) The DEXA-ARDS trial demonstrated mortality benefit with methylprednisolone 1 mg/kg/day tapering over 10 days in patients with severe ARDS (PaO2/FiO2 below 100 mmHg); the proposed mechanism is suppression of surfactant phospholipase A2 activity by glucocorticoid-driven lipocortin-1 upregulation, restoring alveolar surface tension and improving compliance
• E) The DEXA-ARDS trial demonstrated mortality benefit in a subgroup of ARDS patients with blood eosinophils above 200 cells per microliter, confirming that only eosinophilic ARDS phenotypes respond to corticosteroids; non-eosinophilic ARDS does not benefit and may be harmed by dexamethasone through increased bacterial superinfection risk

4. [CASE 1 — QUESTION 4] Continuing with the same patient. Dexamethasone is started. Despite prone positioning for 18 hours and dexamethasone day 1, his PaO2/FiO2 remains at 68 mmHg on FiO2 1.0 with PEEP 16 cmH2O. The ECMO center is contacted but has a 12-hour transfer delay. Inhaled nitric oxide (iNO) at 20 ppm is initiated as a bridge. The fellow asks the team to explain the physiological mechanism of V/Q (ventilation-perfusion) improvement with iNO and why it does not reduce mortality despite improving oxygenation. Which of the following best addresses both questions?

• A) iNO improves V/Q matching by activating sGC (soluble guanylate cyclase) to raise cGMP (cyclic guanosine monophosphate) in all pulmonary vascular smooth muscle equally, reducing pulmonary vascular resistance globally and lowering pulmonary artery pressure; it does not reduce mortality because the reduction in pulmonary artery pressure is offset by decreased right ventricular afterload reduction once iNO is stopped
• B) iNO improves V/Q matching by producing systemic vasodilation that redistributes cardiac output from non-pulmonary vascular beds to the pulmonary circulation, increasing pulmonary perfusion pressure and forcing blood through previously non-perfused but ventilated alveoli; it does not reduce mortality because the systemic hypotension from vasodilation limits the dose that can be safely administered
• C) iNO improves V/Q matching by selectively vasodilating pulmonary vessels adjacent to ventilated alveolar units — where iNO is delivered by inhalation — redirecting blood flow away from non-ventilated flooded regions toward ventilated regions and reducing intrapulmonary shunt; it does not reduce mortality in ARDS because multiple RCTs and the Cochrane systematic review confirm that the oxygenation improvement does not translate to survival benefit in unselected patients, and sGC downregulation from sustained cGMP elevation produces tachyphylaxis within 24 to 72 hours
• D) iNO improves V/Q matching by raising cGMP in alveolar type II pneumocytes, stimulating surfactant secretion into flooded alveoli and restoring surface tension to allow alveolar re-expansion; it does not reduce mortality because surfactant dysfunction in ARDS is irreversible within 72 hours of onset regardless of pharmacological intervention
• E) iNO improves V/Q matching through a non-vascular mechanism — it diffuses into flooded alveolar spaces and oxidizes the fibrin component of hyaline membranes, reducing alveolar flooding and improving diffusion capacity; mortality is not reduced because the fibrinolytic effect is transient and fibrin reaccumulates within 24 hours at the same rate as in untreated alveoli

5. [CASE 2 — QUESTION 1] A 57-year-old woman with moderate ARDS (acute respiratory distress syndrome) secondary to community-acquired pneumonia is intubated on day 1 and started on a propofol infusion at 20 mcg/kg/min, titrated to a RASS (Richmond Agitation-Sedation Scale) target of −2. She also receives fentanyl by continuous infusion for pain. The ICU nutritionist notes that the propofol contribution to total caloric intake has not been accounted for in her enteral nutrition plan. The attending asks the pharmacist to explain propofol's mechanism of sedation, the pharmacokinetic property enabling daily wake-up trials, and the nutritional implication requiring active monitoring. Which of the following correctly addresses all three components?

• A) Propofol produces sedation by antagonizing NMDA (N-methyl-D-aspartate) glutamate receptors in cortical neurons, reducing excitatory neurotransmission; it is suitable for daily wake-up trials because it undergoes renal clearance with a predictable half-life of 2 hours regardless of infusion duration; the nutritional concern is that propofol's glycerol vehicle provides 0.5 kcal/mL of carbohydrate calories requiring inclusion in the glucose management plan
• B) Propofol produces sedation by activating mu-opioid receptors in the thalamus and basal ganglia, producing sedation synergistic with the fentanyl infusion; it supports daily wake-up trials because its short plasma half-life of 30 to 45 minutes is independent of infusion duration; the nutritional concern is that propofol is formulated as a 20 percent fat emulsion providing 2.2 kcal/mL requiring triglyceride surveillance every 24 hours
• C) Propofol produces sedation by potentiating glycine receptor-mediated chloride conductance in the spinal cord and brainstem; it supports daily wake-up trials because its active metabolite 1-hydroxypropofol is cleared renally within 2 to 4 hours; the nutritional concern is that propofol's sorbitol vehicle provides 1.5 kcal/mL of osmotic calories that can cause diarrhea when combined with enteral nutrition
• D) Propofol produces sedation by blocking alpha-1 adrenergic receptors in the ascending reticular activating system, preventing norepinephrine-driven arousal; it is suitable for daily wake-up trials because its non-enzymatic Hofmann elimination produces rapid and organ-independent offset; the nutritional concern is that propofol chelates magnesium in the lipid emulsion vehicle, requiring magnesium supplementation during sustained infusions
• E) Propofol produces sedation by potentiating GABA-A (gamma-aminobutyric acid type A) receptor-mediated chloride conductance; its high lipophilicity produces rapid CNS distribution and redistribution on infusion discontinuation, enabling rapid offset suitable for daily wake-up trials; propofol is formulated in a 10 percent lipid emulsion providing 1.1 kcal/mL — total caloric delivery from the emulsion must be counted in nutrition calculations and serum triglycerides monitored every 48 to 72 hours during sustained or high-dose infusion

6. [CASE 2 — QUESTION 2] Continuing with the same patient. By day 4, propofol has been titrated to 5.4 mg/kg/hour to maintain RASS −3 due to progressive ventilator dyssynchrony. She is also receiving norepinephrine 0.15 mcg/kg/min and methylprednisolone 80 mg IV twice daily for worsening ARDS. Morning results show: pH 7.14, anion gap (AG) 26 mEq/L, serum lactate 5.8 mmol/L, creatine kinase (CK) 11,200 U/L, triglycerides 540 mg/dL, and new right bundle branch block (RBBB) on ECG. Urine is dark brown. Which of the following best identifies the diagnosis, explains why this risk factor constellation lowered the threshold for this complication, and states the most urgent intervention?

• A) This is propofol infusion syndrome (PRIS); high-dose propofol impairs mitochondrial fatty acid oxidation, concurrent norepinephrine increases myocardial and skeletal muscle fatty acid demand beyond the capacity of the impaired mitochondrial oxidation system, and methylprednisolone further suppresses mitochondrial beta-oxidation — the combination produces cellular energy failure in high-demand cardiac and skeletal muscle manifesting as metabolic acidosis, rhabdomyolysis, hypertriglyceridemia, and cardiac conduction abnormality; propofol must be discontinued immediately and an alternative sedative initiated
• B) This is sepsis-induced multiorgan dysfunction superimposed on ARDS; the elevated CK and anion gap reflect hypoperfusion rhabdomyolysis and lactic acidosis from worsening distributive shock requiring vasopressor escalation; the RBBB reflects right ventricular strain from ARDS progression; blood cultures should be obtained and broad-spectrum antibiotics broadened before attributing the findings to propofol in a critically ill patient with known infection
• C) This is hypertriglyceridemia-induced acute pancreatitis from propofol's lipid emulsion accumulating to toxic levels after 4 days of infusion; the rhabdomyolysis is from pancreatic enzyme-mediated muscle injury and the RBBB from electrolyte disturbance caused by pancreatic autodigestion; propofol should be reduced to 2 mg/kg/hour and lipid-free parenteral nutrition substituted for enteral feeds to reduce the combined lipid load
• D) This is methylprednisolone-induced adrenal crisis from HPA (hypothalamic-pituitary-adrenal) axis suppression; the anion gap metabolic acidosis reflects type 4 renal tubular acidosis from mineralocorticoid deficiency, the CK elevation reflects acute corticosteroid myopathy, and the RBBB reflects hyperkalemia-induced conduction delay from aldosterone deficiency; methylprednisolone should be changed to hydrocortisone with mineralocorticoid replacement
• E) This is norepinephrine-induced ischemic myopathy from excessive alpha-1 adrenergic vasoconstriction reducing skeletal muscle perfusion to below the ischemic threshold; the cardiac conduction abnormality reflects coronary vasoconstriction causing ischemia in the right ventricular outflow tract conduction system; norepinephrine should be weaned and vasopressin substituted as a vasopressor without direct alpha-mediated skeletal muscle vasoconstriction

7. [CASE 2 — QUESTION 3] Continuing with the same patient. Propofol is discontinued and dexmedetomidine is initiated at 0.4 mcg/kg/hour without a loading dose. Within 6 hours the patient achieves RASS −1 and is cooperative. The team plans a spontaneous breathing trial (SBT) the following morning. A medical student asks why dexmedetomidine is preferred over midazolam for this transition, and what hemodynamic adverse effects require monitoring during the infusion. Which of the following best addresses both questions?

• A) Dexmedetomidine is preferred over midazolam because its active metabolite alpha-hydroxymidazolam glucuronide is renally cleared and does not accumulate in critically ill patients with normal renal function; the primary hemodynamic adverse effects are hypertension from alpha-1 agonism at low infusion rates and hypotension from alpha-2 agonism at high infusion rates, requiring blood pressure monitoring during any dose change
• B) Dexmedetomidine is preferred over midazolam because it undergoes organ-independent Hofmann elimination, ensuring predictable sedation offset regardless of hepatic or renal function; the primary hemodynamic adverse effects are tachycardia from reflex sympathetic activation and hypertension from baroreceptor-mediated catecholamine surge, requiring continuous cardiac monitoring
• C) Dexmedetomidine is preferred over midazolam because its alpha-2 adrenergic receptor agonism at the locus coeruleus produces cooperative NREM sleep-like sedation that preserves sleep architecture and does not suppress respiratory drive, while benzodiazepines disrupt sleep architecture and are associated with substantially higher delirium rates; the primary hemodynamic adverse effects of dexmedetomidine are bradycardia from reduced sympathetic outflow to the sinoatrial node and hypotension from inhibition of norepinephrine release at peripheral sympathetic nerve terminals
• D) Dexmedetomidine is preferred over midazolam because it produces broader GABA-A receptor subunit selectivity than midazolam, specifically targeting alpha-1 GABA-A subunits associated with sedation while sparing alpha-2 subunits associated with anxiolysis, producing sedation without the paradoxical agitation that midazolam causes through alpha-2 GABA-A subunit stimulation in critically ill patients
• E) Dexmedetomidine is preferred over midazolam because it is a prodrug activated by pulmonary endothelial esterases to an active alpha-methylnorepinephrine metabolite that selectively binds presynaptic alpha-2 receptors; the primary hemodynamic concern is pulmonary hypertension from the accumulation of the active metabolite in patients with ARDS-associated pulmonary vascular injury

8. [CASE 2 — QUESTION 4] Continuing with the same patient. The following morning, the team prepares for the SBT. The dexmedetomidine is weaned and the patient's RASS is 0. She has not received any neuromuscular blocking agents during her ICU stay. Her pain score using the behavioral pain scale (BPS) is 8 (significant pain), suggesting inadequate analgesia. Her fentanyl infusion has been running at 25 mcg/hour. Which of the following correctly describes the complete pharmacological checklist that should be confirmed before initiating the SBT, and what the high BPS score indicates about the correct order of interventions?

• A) The SBT should be initiated immediately because RASS 0 confirms adequate arousal; the high BPS score of 8 should be addressed after the SBT attempt because pain assessment during an active SBT provides more accurate data than a pre-SBT assessment, and treating pain before the SBT with opioids risks respiratory rate suppression that would invalidate the trial
• B) Before initiating the SBT, the team must confirm: RASS 0 to −1 with the patient following simple commands; absence of residual neuromuscular blockade if an NMBA was used (TOF 4/4 or appropriate reversal); and adequate analgesia confirmed by pain scale — the BPS of 8 indicates significant uncontrolled pain that must be treated first because the PADIS (Pain, Agitation/sedation, Delirium, Immobility, and Sleep disruption) analgesia-first paradigm recognizes that uncontrolled pain drives tachypnea, accessory muscle use, and apparent respiratory failure that would cause an SBT to fail even when the patient's respiratory mechanics are adequate for extubation
• C) The SBT checklist includes only hemodynamic and ventilatory criteria — specifically vasopressor independence, FiO2 below 0.4, PEEP below 8 cmH2O, and adequate oxygenation; pain management is part of post-extubation care and is not a prerequisite for SBT initiation because the BPS assesses pain-related behaviors that naturally normalize during the arousal of the SBT without requiring pharmacological intervention
• D) The high BPS score of 8 should be addressed by increasing the dexmedetomidine infusion rather than escalating opioid analgesia; dexmedetomidine provides spinal alpha-2-mediated analgesia that is equivalent to fentanyl at RASS −1, and increasing sedation depth will simultaneously control pain and optimize arousal for the SBT without opioid-related respiratory effects
• E) The SBT should be preceded by naloxone 0.4 mg IV to antagonize the fentanyl infusion and eliminate any opioid-related respiratory suppression; after naloxone administration the SBT can proceed with the BPS score expected to improve as opioid-induced sedation resolves and the patient's pain perception returns to baseline

9. [CASE 3 — QUESTION 1] A 71-year-old man with severe ARDS (acute respiratory distress syndrome) and concurrent hepatic cirrhosis (Child-Pugh class B) and stage 3 chronic kidney disease (CKD) is mechanically ventilated with persistent ventilator dyssynchrony unresolved by optimized sedation at RASS −3. The intensivist decides to initiate a neuromuscular blocking agent (NMBA) infusion. A pharmacist recommends cisatracurium over rocuronium for sustained infusion. A fellow asks why cisatracurium is preferred given the patient's organ impairment, what the current evidence base says about routine NMBA use in ARDS, and what TOF (train-of-four) target should be maintained. Which of the following correctly addresses all three components?

• A) Cisatracurium is preferred because it is renally eliminated and renal clearance is preserved in stage 3 CKD at his estimated GFR; the ACURASYS trial demonstrated definitive and replicated mortality benefit from routine NMB in all ARDS patients, establishing cisatracurium as standard of care for moderate-to-severe ARDS; the TOF target during infusion is 0 out of 4 twitches to ensure complete elimination of dyssynchrony
• B) Cisatracurium is preferred because it is hepatically glucuronidated to inactive metabolites and glucuronidation is preserved even in Child-Pugh class B cirrhosis; the ROSE trial replicated the ACURASYS mortality benefit, confirming routine NMB as superior to light sedation in all ARDS patients; the TOF target is 3 to 4 out of 4 twitches to minimize the depth of block needed
• C) Cisatracurium is preferred because it shares hepatic metabolism with rocuronium but undergoes additional renal tubular secretion that is enhanced in CKD through compensatory hyperfiltration; neither ACURASYS nor ROSE demonstrated definitive mortality benefit, so the current evidence is equipoise and cisatracurium should only be used as a third-line intervention after failure of two alternative sedation strategies
• D) Cisatracurium is preferred because it undergoes organ-independent elimination via Hofmann elimination and plasma esterase hydrolysis — clearance is independent of both hepatic and renal function, critical in this patient with multiorgan impairment; the ACURASYS trial showed mortality benefit but the larger ROSE trial found no benefit when using a light sedation control arm, so current practice reserves routine NMB for patients with refractory dyssynchrony, refractory hypoxemia, or prone positioning facilitation rather than applying it universally; TOF target during infusion is 1 to 2 out of 4 twitches
• E) Cisatracurium is preferred because it is a depolarizing NMBA with ultra-short duration allowing dose titration without accumulation in organ failure; the ACURASYS and ROSE trials both showed significant mortality reduction from early NMB in severe ARDS, supporting universal application; TOF monitoring is unnecessary for depolarizing NMBAs because duration is determined by plasma pseudocholinesterase activity rather than receptor occupancy

10. [CASE 3 — QUESTION 2] Continuing with the same patient. Cisatracurium is initiated and TOF is maintained at 1 to 2 out of 4 twitches for 60 hours. The patient is also receiving dexamethasone for ARDS per the DEXA-ARDS protocol. On day 8, the cisatracurium infusion is stopped, TOF recovers to 4/4 within 4 hours, but 3 days later the patient remains unable to lift his arms against gravity or generate sufficient inspiratory force to sustain an SBT beyond 10 minutes. He is alert, RASS 0, and follows all commands. Which of the following best explains the mechanisms underlying his persistent weakness and identifies the prevention strategy that should be applied in future cases?

• A) Persistent weakness despite TOF 4/4 reflects ongoing cisatracurium activity from delayed Hofmann elimination in his cirrhotic and CKD state; the correct management is sugammadex 16 mg/kg IV to encapsulate residual cisatracurium molecules in plasma, which will resolve the weakness within 15 minutes; future prevention requires avoiding cisatracurium in patients with any degree of renal impairment
• B) Persistent weakness with TOF 4/4 reflects complete and irreversible destruction of neuromuscular junction (NMJ) architecture from 60 hours of NMJ blockade, producing a permanent myasthenic state analogous to acquired myasthenia gravis; future prevention requires limiting NMBA duration to 24 hours maximum regardless of clinical indication
• C) Persistent weakness reflects depletion of motor neuron acetylcholine (ACh) vesicle stores from 60 hours of forced inactivity at the NMJ; vesicle replenishment requires 5 to 10 days of spontaneous NMJ activity to restore quantal ACh content; future prevention involves pre-loading with neostigmine 30 minutes before NMBA discontinuation to stimulate vesicle replenishment
• D) Persistent weakness with TOF 4/4 reflects respiratory muscle deconditioning from 60 hours of mechanical ventilation rather than a pharmacological complication of NMB; the appropriate management is progressive inspiratory muscle training starting at 20 percent of maximal inspiratory pressure; future prevention requires early tracheostomy in all patients expected to require more than 48 hours of mechanical ventilation
• E) Persistent weakness despite TOF 4/4 is ICU-acquired weakness (ICUAW), caused by three converging mechanisms: disuse atrophy from complete motor unit suppression during cisatracurium infusion, corticosteroid myopathy from dexamethasone driving ubiquitin-proteasome protein catabolism and suppressing IGF-1-mTOR synthesis, and critical illness polyneuropathy and myopathy (CIP/CIM) from the systemic inflammatory milieu; future prevention includes limiting NMB duration to the minimum clinically necessary, maintaining TOF at 1 to 2 out of 4 rather than zero, avoiding concurrent corticosteroids where clinically feasible, and initiating early physical therapy after NMB discontinuation

11. [CASE 3 — QUESTION 3] Continuing with the same patient. Three weeks later, following successful extubation and rehabilitation, the patient requires urgent re-intubation for a new aspiration event. The anesthesiologist administers rocuronium 1.2 mg/kg IV for RSI (rapid-sequence intubation). After two failed laryngoscopy attempts with worsening desaturation (SpO2 now 74%), the team declares a CICO (cannot-intubate, cannot-oxygenate) emergency and decides to reverse the paralysis to restore spontaneous ventilation while preparing for a surgical airway. TOF shows 0 out of 4 twitches. A trainee recommends neostigmine 5 mg IV. Which of the following correctly explains why neostigmine is inadequate and identifies the correct reversal agent, dose, and mechanism?

• A) Neostigmine is inadequate because it requires hepatic conversion to its active cholinesterase-inhibiting form, and this patient's cirrhosis impairs hepatic bioactivation; the correct agent is sugammadex 4 mg/kg IV, which bypasses the need for hepatic activation by encapsulating rocuronium directly; 4 mg/kg is sufficient for moderate block and avoids the bradycardia risk of higher doses
• B) Neostigmine is inadequate because rocuronium at 1.2 mg/kg binds nAChRs (nicotinic acetylcholine receptors) irreversibly, and neostigmine cannot displace irreversibly bound NMBAs; the correct agent is sugammadex 8 mg/kg, which covalently modifies the rocuronium molecule in the synaptic cleft to restore nAChR function; 8 mg/kg is the standard dose for immediate reversal of any rocuronium dose
• C) Neostigmine is inadequate at deep block because its mechanism — acetylcholinesterase inhibition raising synaptic ACh — cannot overcome near-complete nAChR occupancy by rocuronium when TOF is zero; the correct agent is sugammadex 16 mg/kg IV, which encapsulates free rocuronium in plasma as a modified gamma-cyclodextrin in a 1:1 stoichiometric complex, lowering plasma rocuronium concentration by mass action and driving dissociation from nAChRs — restoring neuromuscular transmission within 3 minutes regardless of block depth
• D) Neostigmine is inadequate because TOF of zero indicates complete cisatracurium block rather than rocuronium block, and neostigmine cannot reverse benzylisoquinolinium NMBAs; the correct agent is sugammadex 16 mg/kg, which reverses both aminosteroid and benzylisoquinolinium NMBAs through its gamma-cyclodextrin encapsulation mechanism
• E) Neostigmine is inadequate in this patient because his severe cirrhosis reduces plasma pseudocholinesterase production, and pseudocholinesterase is required to activate neostigmine; the correct agent is edrophonium 10 mg/kg IV, which does not require pseudocholinesterase activation and produces complete rocuronium reversal through a different acetylcholinesterase inhibition mechanism at the NMJ

12. [CASE 3 — QUESTION 4] Continuing with the same patient. Following successful re-intubation with a surgical airway and resolution of his aspiration event, he is re-mechanically ventilated. After 12 days of total intubation he again meets extubation criteria and passes an SBT. Cuff leak test reveals minimal cuff leak volume. The team asks for the pharmacological prevention protocol, the mechanistic rationale for the timing requirement, and what to do if post-extubation stridor occurs despite prophylaxis. Which of the following correctly addresses all three components?

• A) The prevention protocol is methylprednisolone 20 mg IV every 4 hours for 4 doses beginning 12 hours before planned extubation, supported by the TOP (Treatment of Post-Extubation Stridor) trial; the 12-hour timing requirement exists because corticosteroids produce their anti-edema effects through genomic mechanisms — transcriptional suppression of inflammatory cytokines and reduction of mucosal vascular permeability — requiring hours to manifest at the protein level before the ETT (endotracheal tube) is removed; if post-extubation stridor occurs despite prophylaxis, nebulized racemic epinephrine produces immediate local laryngeal vasoconstriction and temporary edema reduction as a bridge to deciding whether reintubation is required
• B) The prevention protocol is dexamethasone 10 mg IV as a single dose given immediately before extubation; the immediate pre-extubation timing is required because dexamethasone acts through non-genomic membrane receptor pathways that produce anti-edema effects within 5 to 10 minutes of administration; if post-extubation stridor occurs, IV methylprednisolone should replace the dexamethasone because dexamethasone's short duration of action will have worn off by the time stridor develops
• C) The prevention protocol is hydrocortisone 200 mg IV once, given 24 hours before extubation for its combined anti-inflammatory and hemodynamic stabilization effects; the 24-hour timing requirement reflects the pharmacokinetic half-life of hydrocortisone in ICU patients with impaired hepatic metabolism from his cirrhosis; if post-extubation stridor occurs, heliox should be administered to reduce airway resistance until the hydrocortisone anti-inflammatory effect fully manifests 24 to 48 hours after the dose
• D) The prevention protocol is inhaled budesonide delivered via the endotracheal tube every 6 hours starting 12 hours before extubation; inhaled delivery is preferred because it delivers corticosteroid directly to the laryngeal mucosa at the site of ETT injury without systemic immunosuppression; if post-extubation stridor occurs, the inhaled budesonide should be continued via face mask as a corticosteroid maintenance strategy
• E) The prevention protocol is methylprednisolone 40 mg IV every 8 hours for 3 doses beginning 24 hours before planned extubation; the 24-hour window is required because this patient's cirrhosis slows hepatic conversion of methylprednisolone to its active form prednisolone, necessitating earlier administration to ensure adequate active drug tissue levels at the laryngeal mucosa at the time of extubation

13. [CASE 4 — QUESTION 1] A 48-year-old woman with severe ARDS (acute respiratory distress syndrome) from bacterial sepsis has a PaO2/FiO2 (ratio of partial pressure of arterial oxygen to fraction of inspired oxygen) of 61 mmHg on FiO2 (fraction of inspired oxygen) 1.0 with PEEP (positive end-expiratory pressure) 18 cmH2O, despite 16 hours of prone positioning and dexamethasone. Inhaled nitric oxide (iNO) is initiated at 20 ppm as rescue oxygenation. The attending briefs the team on expected response, monitoring requirements during administration, and the critical safety parameter to check within the first 4 hours. Which of the following correctly describes the expected oxygenation response, mechanism, and the primary monitoring requirement?

• A) iNO at 20 ppm is expected to restore PaO2/FiO2 to above 300 mmHg in most patients with severe ARDS within 4 hours through its anti-inflammatory effects on the alveolar-capillary membrane; the primary monitoring requirement during administration is serial chest radiographs every 6 hours to detect alveolar flooding from cGMP-mediated increased vascular permeability
• B) iNO at 20 ppm is expected to produce a PaO2/FiO2 improvement of approximately 10 to 25 percent within 4 hours through selective pulmonary vasodilation in ventilated alveolar units, redirecting blood flow from non-ventilated to ventilated regions and reducing intrapulmonary shunt; the primary monitoring requirement is methemoglobin (MetHb) level every 4 to 8 hours, as iNO oxidizes oxyhemoglobin to MetHb which cannot carry oxygen, and levels above 3 percent warrant dose reduction
• C) iNO at 20 ppm is expected to produce sustained oxygenation improvement lasting 7 to 14 days through progressive downregulation of endothelin-1 receptors in the pulmonary vasculature; the primary monitoring requirement is serial nitrogen dioxide (NO2) levels measured in the delivery circuit, and levels above 10 ppm mandate circuit flushing before the next dose cycle
• D) iNO produces its oxygenation benefit by restoring surfactant function in flooded alveoli — cGMP activates protein kinase G in type II pneumocytes, stimulating surfactant phospholipid secretion; the primary monitoring requirement is surfactant protein B levels in bronchoalveolar lavage every 24 hours to confirm response and guide dose adjustment
• E) iNO at 20 ppm is expected to reduce pulmonary artery pressure to normal within 6 hours in patients with severe ARDS through global pulmonary vasodilation; the primary monitoring requirement is invasive pulmonary artery catheter placement to measure pulmonary vascular resistance continuously, as a failure to achieve a 50 percent reduction in PVR within 6 hours indicates primary pulmonary hypertension rather than ARDS

14. [CASE 4 — QUESTION 2] Continuing with the same patient. Eighteen hours into iNO therapy, routine co-oximetry shows a MetHb (methemoglobin) level of 5.2 percent. Pulse oximetry reads SpO2 92 percent, but co-oximetry confirms true oxyhemoglobin saturation of 86 percent. The iNO dose has remained at 20 ppm. The patient is hemodynamically stable with HR 88, BP 118/72 mmHg, and no change in mentation. Which of the following correctly identifies the clinical significance of this MetHb level, explains the SpO2 discrepancy, and states the appropriate management?

• A) A MetHb of 5.2 percent is a medical emergency requiring immediate methylene blue 2 mg/kg IV and iNO discontinuation; MetHb above 5 percent universally causes symptomatic tissue hypoxia requiring antidote regardless of clinical status, and the SpO2 of 92 percent overestimates true saturation because pulse oximetry absorbs at 660 nm where oxyhemoglobin and MetHb have identical spectral profiles
• B) A MetHb of 5.2 percent is clinically inconsequential because therapeutic iNO at 1 to 40 ppm always produces MetHb in the 4 to 7 percent range as an expected pharmacodynamic effect; no dose adjustment is required; the SpO2 discrepancy reflects a co-oximeter calibration error since pulse oximetry is more accurate than co-oximetry for MetHb levels below 10 percent
• C) A MetHb of 5.2 percent indicates methemoglobin reductase deficiency confirmed by the level achieved at a standard iNO dose; iNO must be permanently discontinued and may never be re-administered; inhaled epoprostenol must be substituted immediately and the patient screened for other oxidant drug exposures that will be permanently contraindicated
• D) A MetHb of 5.2 percent exceeds the generally accepted threshold of 3 percent for clinical inconsequence at therapeutic iNO doses, indicating MetHb formation is occurring beyond the patient's reductase clearance capacity; the SpO2 discrepancy occurs because pulse oximetry cannot distinguish MetHb from oxyhemoglobin and overestimates true oxygenation — co-oximetry confirms a clinically real oxygen-carrying deficit; the iNO dose should be reduced and MetHb rechecked in 2 to 4 hours, with iNO discontinuation if MetHb continues to rise
• E) A MetHb of 5.2 percent confirms that the current iNO dose of 20 ppm is providing maximal therapeutic benefit, as the degree of MetHb formation directly correlates with the degree of pulmonary vascular sGC activation; reducing the iNO dose to lower MetHb will proportionally reduce oxygenation benefit, so the team should maintain 20 ppm and accept the MetHb level as the pharmacodynamically necessary cost of efficacy

15. [CASE 4 — QUESTION 3] Continuing with the same patient. After 3 days of iNO with initial PaO2/FiO2 improvement from 61 to 108 mmHg, her oxygenation has stabilized. The iNO dose was reduced from 20 to 10 ppm 30 minutes ago. Her SpO2 has now fallen from 93 percent to 78 percent and pulmonary artery pressure has increased sharply on the monitor. FiO2 has been increased to 1.0 with minimal response. Which of the following best explains the mechanism of this deterioration and the correct immediate and subsequent management strategy?

• A) The deterioration reflects progressive sGC (soluble guanylate cyclase) downregulation from 3 days of iNO that has now reached a threshold below which the reduced enzyme population cannot produce adequate cGMP even at the original 20 ppm dose; restoring to 20 ppm will not help because sGC expression cannot recover — the only effective rescue is immediate transition to inhaled epoprostenol, which uses a completely different cAMP pathway unaffected by sGC downregulation
• B) The deterioration reflects MetHb accumulation reaching a critical threshold following the dose reduction; when iNO is reduced, residual MetHb clears more slowly than new oxyhemoglobin forms, transiently worsening functional oxygen-carrying capacity; the correct management is methylene blue 1 mg/kg IV to restore MetHb to oxyhemoglobin, then slowly re-wean iNO over 12 hours
• C) The deterioration reflects NO2 (nitrogen dioxide) toxicity in the delivery circuit; at lower iNO concentrations, the ratio of NO2 to iNO in the circuit increases because NO2 formation is concentration-independent while iNO delivery decreases; the correct management is circuit flushing with oxygen before resuming iNO at the original dose
• D) The deterioration reflects acute right ventricular decompensation from the removal of iNO's preload-reducing effect on the right ventricle; iNO at 20 ppm was sustaining right ventricular output by reducing pulmonary vascular resistance below the right ventricular pressure-generating capacity; restoring iNO is incorrect — the appropriate management is intravenous milrinone to support right ventricular contractility independent of vasodilator therapy
• E) The deterioration reflects suppression of endogenous NOS (nitric oxide synthase) activity during 3 days of iNO therapy; when iNO is reduced, endogenous NOS remains suppressed and cannot compensate, causing acute pulmonary vasoconstriction and worsened V/Q matching; iNO should be restored to 20 ppm immediately to restabilize oxygenation, then re-weaned far more gradually — approximately 50 percent dose reductions every 4 hours with close SpO2 monitoring — to allow endogenous NOS recovery at each step

16. [CASE 4 — QUESTION 4] Continuing with the same patient. After a successful gradual iNO wean over 48 hours, her oxygenation has improved sufficiently that rescue vasodilator therapy is no longer required. However, her ARDS remains moderate and a colleague asks whether inhaled epoprostenol would have been a reasonable alternative to iNO from the outset, and how its mechanism and evidence profile compare. Which of the following correctly contrasts inhaled epoprostenol with iNO in terms of mechanism, evidence, and practical considerations?

• A) Inhaled epoprostenol activates prostacyclin IP receptors coupled to Gs proteins, raising cAMP (cyclic adenosine monophosphate) via adenylyl cyclase in pulmonary vascular smooth muscle — a mechanism distinct from iNO's sGC-cGMP pathway; it produces comparable V/Q improvement and oxygenation benefit to iNO in ARDS with a less robust evidence base, but offers practical advantages of lower cost and absence of specialized delivery infrastructure, MetHb monitoring, and NO2 monitoring requirements
• B) Inhaled epoprostenol and iNO share the identical mechanism — both activate sGC to raise cGMP — because inhaled prostacyclin is metabolized in the lung to a nitric oxide prodrug that releases NO to activate sGC; the advantage of inhaled epoprostenol over iNO is its longer half-life of 30 to 60 minutes in blood, allowing intermittent rather than continuous delivery and reducing nursing workload
• C) Inhaled epoprostenol is superior to iNO in randomized controlled trials of ARDS because it produces oxygenation improvement at lower doses than iNO and also reduces mortality at 28 days, unlike iNO which improves oxygenation without mortality benefit; it should therefore be used as first-line rescue oxygenation therapy rather than iNO in all ARDS patients
• D) Inhaled epoprostenol produces oxygenation improvement only in pulmonary arterial hypertension-associated hypoxemia, not in ARDS-associated hypoxemia; in ARDS the V/Q mismatch is from alveolar flooding rather than pulmonary vascular disease, and prostacyclin IP receptor activation cannot redirect blood flow in an alveolar-flooding context the way that iNO sGC activation can
• E) Inhaled epoprostenol is preferred over iNO in ARDS complicated by thrombocytopenia because prostacyclin IP receptor activation inhibits platelet aggregation through the same cAMP pathway, providing dual benefit of oxygenation improvement and thrombocytopenia-sparing antiplatelet prophylaxis that reduces the risk of HIT (heparin-induced thrombocytopenia) progression to arterial thrombosis

17. [CASE 5 — QUESTION 1] A 62-year-old man with severe COPD (chronic obstructive pulmonary disease) and FEV1 28 percent of predicted is mechanically ventilated for an acute exacerbation. Bronchospasm has been treated with optimized inhaled bronchodilators and systemic corticosteroids. Despite three failed SBTs (spontaneous breathing trials) over 5 days showing rapid shallow breathing and diaphragmatic fatigue on ultrasound, he has not extubated. The pulmonologist initiates aminophylline with a specific weaning goal. The team asks what mechanisms underlie theophylline's weaning benefit, distinct from bronchodilation, and what plasma concentration should be targeted for this indication. Which of the following is correct?

• A) Theophylline improves weaning by activating beta-2 adrenergic receptors in the diaphragm to increase contractile force, and by blocking central A2A adenosine receptors to increase ventilatory drive; the target concentration for these weaning-specific effects is 15 to 20 mcg/mL, the same range required for bronchodilation, to achieve full PDE (phosphodiesterase) inhibition in respiratory muscle
• B) Theophylline improves weaning through two mechanisms independent of bronchodilation: PDE inhibition in diaphragmatic muscle raises cAMP (cyclic adenosine monophosphate), improving contractility and fatigue resistance; and adenosine A1 and A2A receptor antagonism in brainstem respiratory centers increases central respiratory drive; the target plasma concentration for these weaning-specific effects is 8 to 12 mcg/mL — below the standard bronchodilatory range — providing a meaningful safety margin below the toxicity threshold of 20 mcg/mL
• C) Theophylline improves weaning by inhibiting PDE4 selectively in diaphragmatic muscle at plasma concentrations of 3 to 5 mcg/mL; at these very low subtherapeutic concentrations, PDE4 in muscle is fully inhibited while PDE3 in cardiac tissue remains unaffected, preventing arrhythmia risk; targeting above 5 mcg/mL adds cardiac PDE3 inhibition without additional respiratory muscle benefit
• D) Aminophylline contains active theophylline and an inactive ethylenediamine carrier; the ethylenediamine component independently stimulates phrenic nerve conduction velocity, and this non-theophylline mechanism accounts for the majority of weaning benefit; theophylline plasma levels do not need to be monitored when aminophylline is used specifically for weaning because the phrenic nerve effect is dose-independent
• E) Theophylline improves weaning by competitively blocking adenosine A1 receptors at the neuromuscular junction (NMJ), restoring the end-plate potential amplitude that is reduced by adenosine-mediated presynaptic inhibition of ACh release during diaphragmatic fatigue; the target concentration is 12 to 18 mcg/mL to achieve sufficient NMJ adenosine blockade while avoiding the supratherapeutic arrhythmia risk above 20 mcg/mL

18. [CASE 5 — QUESTION 2] Continuing with the same patient. Aminophylline loading and maintenance infusion are initiated. On day 2, his serum theophylline level returns at 24 mcg/mL. Telemetry shows new onset atrial fibrillation with rapid ventricular response (HR 138 bpm). He reports nausea and has vomited twice. He has no prior history of atrial fibrillation. Which of the following correctly identifies the pharmacological explanation for the arrhythmia at this concentration and the appropriate management?

• A) A theophylline level of 24 mcg/mL is within the upper therapeutic range; atrial fibrillation at this level reflects the patient's underlying COPD-related cardiac remodeling rather than theophylline toxicity; a rate-control agent such as diltiazem should be added and aminophylline continued at the current infusion rate with repeat level in 24 hours
• B) A theophylline level of 24 mcg/mL indicates subtherapeutic dosing for this patient who has an elevated volume of distribution from his COPD; the atrial fibrillation is a manifestation of his underlying respiratory failure and would respond to improved oxygenation from increased aminophylline dosing; the loading dose should be repeated
• C) A theophylline level of 24 mcg/mL exceeds the established toxicity threshold of 20 mcg/mL; at this supratherapeutic level theophylline inhibits a broader range of PDE isoforms including PDE3 in cardiac myocytes, raising cAMP and increasing automaticity and shortening action potential duration to produce atrial fibrillation; aminophylline should be held immediately, rate control addressed, and the level rechecked after an appropriate washout interval before considering a lower maintenance dose
• D) A theophylline level of 24 mcg/mL is toxic because theophylline directly blocks cardiac voltage-gated potassium channels at concentrations above 22 mcg/mL, producing QT prolongation and triggered arrhythmia through early afterdepolarizations; the antidote is magnesium sulfate 2 g IV to restore potassium channel function, followed by aminophylline dose reduction to target 12 to 16 mcg/mL
• E) A theophylline level of 24 mcg/mL produces atrial fibrillation through adenosine A2A receptor blockade in the atrial conduction system; because A2A receptors normally suppress automaticity in atrial pacemaker tissue, their blockade disinhibits automaticity and produces supraventricular arrhythmia; the treatment is adenosine 6 mg IV as first-line to restore A2A-mediated atrial suppression before attempting electrical cardioversion

19. [CASE 5 — QUESTION 3] Continuing with the same patient. Aminophylline is held for 18 hours. The atrial fibrillation converts spontaneously. His theophylline level is now 12 mcg/mL. The team restarts aminophylline at a reduced maintenance infusion rate targeting a steady-state concentration of 10 mcg/mL. The patient's RASS is 0, BPS (behavioral pain scale) suggests adequate analgesia, and he has not received any NMBA. The team plans to attempt an SBT the next morning. Which of the following correctly identifies the full pharmacological readiness checklist for this patient's SBT, and why the theophylline level at 10 mcg/mL is now appropriate for the weaning goal?

• A) The full SBT checklist is RASS 0 to −1 and confirmed reversal of all sedative drug effects by flumazenil and naloxone challenge; theophylline at 10 mcg/mL is appropriate because this level produces maximum PDE4 inhibition in the diaphragm while completely avoiding PDE3 inhibition in cardiac tissue, confirmed by the absence of arrhythmia at this level
• B) The full SBT checklist is SpO2 above 94 percent on FiO2 below 0.4 and PEEP below 8 cmH2O; theophylline at 10 mcg/mL is appropriate because this is the minimum concentration required to produce adenosine receptor blockade sufficient to overcome endogenous adenosine accumulation in fatigued diaphragmatic tissue during the SBT
• C) The full SBT checklist requires vasopressor independence for at least 24 hours prior to the trial, RASS 0 to −1, and FiO2 below 0.5; theophylline at 10 mcg/mL is subtherapeutic for this indication and the dose should be increased to 15 mcg/mL before the SBT to ensure maximal diaphragmatic contractility improvement
• D) The full pharmacological readiness checklist is: RASS 0 to −1 with the patient following simple commands (confirmed); adequate analgesia confirmed by validated pain scale such as BPS (confirmed); and absence of residual neuromuscular blockade confirmed by TOF 4/4 or appropriate reversal (no NMBA administered, so confirmed by history); theophylline at 10 mcg/mL is within the 8 to 12 mcg/mL range targeting diaphragmatic contractility improvement and central respiratory drive via PDE inhibition and adenosine A1/A2A antagonism — the therapeutic range for the weaning indication that provides benefit while maintaining a safety margin below the 20 mcg/mL toxicity threshold
• E) The full SBT checklist for this patient additionally requires documented absence of atrial fibrillation for at least 48 hours and a theophylline level below 15 mcg/mL; theophylline at 10 mcg/mL is appropriate, but the SBT should be postponed until 48 hours of documented sinus rhythm to ensure cardiac stability before increasing respiratory demands during the trial

20. [CASE 5 — QUESTION 4] Continuing with the same patient. He successfully extubates on the next SBT attempt. The team considers transitioning him from IV aminophylline to oral theophylline for outpatient use to support ongoing respiratory muscle function and bronchodilation in his severe COPD. The pharmacist flags that TDM (therapeutic drug monitoring) will be essential and that several factors specific to this patient's drug regimen and comorbidities will affect clearance and steady-state levels. Which of the following correctly identifies why TDM is mandatory for theophylline and identifies at least two specific factors in this patient's clinical context that alter theophylline clearance?

• A) TDM is mandatory because theophylline follows zero-order kinetics at all plasma concentrations, producing disproportionate level rises with small dose increases due to enzyme saturation; factors increasing clearance in this patient include his COPD (which upregulates CYP1A2 through hypoxia-induced transcription factor activation) and his age over 60 (which paradoxically increases CYP1A2 activity in smokers through induction)
• B) TDM is mandatory because theophylline is eliminated exclusively by renal filtration of the unchanged parent molecule, and this patient's CKD reduces GFR-dependent clearance unpredictably; factors decreasing clearance include active smoking (which reduces renal tubular secretion through nicotine-induced vasoconstriction) and macrolide antibiotics (which block renal organic anion transporters)
• C) TDM is mandatory because theophylline is a prodrug activated by CYP1A2, and interindividual variation in CYP1A2 expression produces wide variation in active drug formation from a standard aminophylline dose; factors decreasing activation in this patient include advanced age (which reduces CYP1A2 induction capacity) and ciprofloxacin (if prescribed for a respiratory infection, it blocks CYP1A2-mediated theophylline activation)
• D) TDM is mandatory because theophylline has a narrow therapeutic index — the therapeutic range of 8 to 20 mcg/mL is close to the toxicity threshold of 20 mcg/mL — and follows first-order kinetics in the therapeutic range but switches to saturable zero-order kinetics above 20 mcg/mL, making level prediction unreliable once toxicity begins; factors altering clearance in this patient include his tobacco smoking history (smoking induces CYP1A2 and increases theophylline clearance) and any macrolide or fluoroquinolone antibiotics prescribed for respiratory infections (which inhibit CYP1A2 and raise theophylline levels)
• E) TDM is mandatory because theophylline has a narrow therapeutic index (therapeutic 8 to 20 mcg/mL, toxicity above 20 mcg/mL) and wide interindividual pharmacokinetic variability; factors that reduce theophylline clearance and raise plasma levels in this patient include his age (reduced CYP1A2 activity in older patients), hepatic impairment from cor pulmonale-related hepatic congestion if present (reduced hepatic CYP1A2 metabolism), heart failure (reduced hepatic perfusion and metabolism), and any fluoroquinolone or macrolide antibiotics prescribed for respiratory infections (both inhibit CYP1A2, raising theophylline levels into the toxic range)

21. [CASE 6 — QUESTION 1] A 53-year-old woman is mechanically ventilated for 11 days following moderate ARDS from community-acquired pneumonia. Her infection has responded to antibiotics, oxygenation is adequate on FiO2 0.35 and PEEP 6 cmH2O, and she passes today's SBT (spontaneous breathing trial) at RASS 0. The respiratory therapist performs a cuff leak test and measures a cuff leak volume of 40 mL — flagged as high-risk for post-extubation laryngeal edema (a cuff leak below 110 mL is considered high-risk at many centers). Extubation is planned for the following morning at 8 AM. The team asks the pharmacist for the pharmacological prevention protocol, why the timing requirement is mechanistically non-negotiable, and what clinical outcome the evidence supports. Which of the following is correct?

• A) The protocol is methylprednisolone 20 mg IV every 4 hours for 4 doses beginning at 8 PM tonight (12 hours before planned extubation); the timing is non-negotiable because corticosteroids produce anti-edema effects through genomic mechanisms — binding intracellular glucocorticoid receptors, driving nuclear translocation, and suppressing transcription of inflammatory cytokines and vascular permeability mediators — requiring several hours of protein-level change to reduce laryngeal mucosal edema before the ETT (endotracheal tube) is removed; the TOP trial demonstrated reduction in post-extubation stridor from approximately 22 percent to 7 percent and reduction in reintubation rates in high-risk patients
• B) The protocol is dexamethasone 4 mg IV once at 8 PM tonight; the timing of the evening before extubation is based on dexamethasone's longer glucocorticoid receptor occupancy half-life compared with methylprednisolone, which requires only a single dose to achieve 12 hours of continuous receptor activation; the TOP trial demonstrated that single-dose dexamethasone the evening before extubation is superior to multi-dose methylprednisolone for reducing post-extubation stridor
• C) The protocol is methylprednisolone 500 mg IV once, given 6 hours before extubation; high-dose corticosteroids reduce mucosal edema more rapidly through non-genomic membrane receptor pathways that produce vasoconstrictive effects within 30 minutes — making the 6-hour window sufficient; the evidence base is the DEXA-ARDS trial, which demonstrated that high-dose dexamethasone reduces post-extubation laryngeal edema as a secondary endpoint
• D) The protocol is inhaled budesonide via nebulizer every 4 hours starting tonight for 3 doses; inhaled delivery targets the laryngeal mucosal surface directly, concentrating corticosteroid at the site of ETT injury without systemic exposure; the evidence base is the TOP trial, which compared inhaled versus systemic corticosteroid and found equivalent efficacy with fewer systemic adverse effects for the inhaled route
• E) No pharmacological prevention is indicated because the cuff leak test is not a validated predictor of post-extubation laryngeal edema and the 40 mL cuff leak volume at this center's threshold of 110 mL has a positive predictive value of less than 20 percent; the risk of corticosteroid-related hyperglycemia and immunosuppression in a patient recovering from pneumonia outweighs the marginal benefit of prophylactic methylprednisolone in patients flagged by cuff leak test alone

22. [CASE 6 — QUESTION 2] Continuing with the same patient. The methylprednisolone protocol is completed and the patient is extubated at 8 AM. Within 25 minutes she develops audible inspiratory stridor and increased work of breathing, with SpO2 falling from 97 percent to 88 percent on 4 L/min nasal cannula. She is distressed but alert. The team asks what pharmacological and non-pharmacological interventions should be used in what order before deciding on reintubation. Which of the following correctly sequences the management and explains the mechanism of the pharmacological intervention?

• A) The first step is to administer IV methylprednisolone 125 mg immediately, recognizing that the earlier doses were insufficient to suppress inflammation and that a higher-dose IV steroid pulse is needed; while waiting for the systemic corticosteroid to take effect over 4 to 6 hours, the patient should be placed in the upright position and supplemental oxygen continued
• B) The first step is to administer nebulized albuterol to reverse bronchospasm at the subglottic level; if oxygenation does not improve within 10 minutes, nebulized ipratropium should be added to provide additive bronchodilation through a complementary mechanism; systemic corticosteroids should be added only if both bronchodilators fail to reverse stridor within 30 minutes
• C) The first step is nebulized racemic epinephrine, which produces rapid local laryngeal vasoconstriction through alpha-1 adrenergic receptor agonism, transiently reducing mucosal edema and airway obstruction; this is combined with upright positioning, supplemental oxygen titration, and heliox (helium-oxygen mixture) if available to reduce turbulent airflow resistance through the narrowed glottis; reintubation is indicated if SpO2 cannot be maintained above 90 to 92 percent or if the patient fatigues despite these measures
• D) The first step is IV dexamethasone 10 mg as a single dose, which acts faster than inhaled agents because systemic delivery bypasses the need for inhalation through an obstructed airway; nebulized racemic epinephrine should be avoided because its alpha-1 agonism causes rebound edema 30 to 60 minutes after administration that is more severe than the original stridor
• E) The first step is immediate reintubation because post-extubation stridor indicates laryngeal edema that has progressed beyond the point of pharmacological rescue; any delay in reintubation to attempt pharmacological management risks complete airway obstruction; racemic epinephrine and heliox may be administered simultaneously with reintubation preparation but should not delay securing the airway

23. [CASE 6 — QUESTION 3] Continuing with the same patient. Nebulized racemic epinephrine is administered twice over 90 minutes with good response — stridor resolves and SpO2 improves to 96 percent on 4 L/min nasal cannula. She is monitored closely and stridor does not recur over the following 4 hours. The team considers whether any additional pharmacological management is needed overnight to prevent recurrence and identifies the key monitoring concern after racemic epinephrine administration. Which of the following correctly identifies what monitoring is required after racemic epinephrine use in post-extubation stridor and what, if any, additional pharmacological management is appropriate?

• A) After racemic epinephrine administration, no specific monitoring is required because the drug's half-life of 4 to 6 hours ensures sustained mucosal vasoconstriction throughout the overnight observation period; no additional pharmacological management is needed as long as SpO2 remains above 90 percent
• B) After racemic epinephrine administration, close observation for rebound edema is required for at least 2 to 4 hours after the last dose because racemic epinephrine's vasoconstriction is temporary — typically lasting 30 to 60 minutes — after which mucosal capillary refilling may cause partial edema rebound; no additional corticosteroid is routinely added post-extubation, but the patient should have easy access to reintubation equipment and personnel throughout the observation period
• C) After racemic epinephrine administration, the patient must receive IV beta-blocker therapy to prevent rebound tachycardia from systemic absorption of inhaled epinephrine through the inflamed subglottic mucosa; systemic absorption is substantial when the airway is edematous and beta-blockade is required to prevent epinephrine-induced atrial fibrillation in the post-extubation period
• D) After racemic epinephrine administration, IV hydrocortisone 100 mg every 8 hours for 24 hours is indicated to prevent rebound edema through sustained mineralocorticoid-mediated reduction in mucosal capillary permeability; hydrocortisone is preferred over methylprednisolone post-extubation because its combined glucocorticoid and mineralocorticoid effects produce superior mucosal drying compared with pure glucocorticoid agents
• E) After racemic epinephrine administration, the patient must be immediately re-intubated for airway safety monitoring because the initial response to racemic epinephrine is reliably followed by rebound stridor more severe than the original episode within 60 minutes, and attempting to manage this rebound pharmacologically while the patient is extubated carries an unacceptable risk of complete airway obstruction

24. [CASE 6 — QUESTION 4] Continuing with the same patient. She is successfully monitored overnight without rebound stridor and is discharged from the ICU the following morning. At a team debrief, a medical student asks why the TOP trial used methylprednisolone 20 mg IV every 4 hours for 4 doses rather than a single larger dose or a different corticosteroid, and what the pharmacological rationale is for the multi-dose approach. Which of the following best explains the rationale for the multi-dose methylprednisolone protocol?

• A) Methylprednisolone is used rather than dexamethasone because methylprednisolone has greater mineralocorticoid activity, and mucosal edema reduction requires both glucocorticoid and mineralocorticoid receptor activation to simultaneously suppress cytokine production and drive sodium reabsorption from the laryngeal interstitium; a single dose of a pure glucocorticoid such as dexamethasone is pharmacodynamically insufficient for the dual-receptor mechanism required
• B) The multi-dose protocol is used because methylprednisolone is a prodrug requiring hepatic conversion to prednisolone before glucocorticoid receptor activation; the 4-hour dosing interval ensures continuous hepatic conversion to maintain steady-state prednisolone levels throughout the 12-hour pre-extubation window, whereas a single large methylprednisolone dose would be fully converted and cleared before extubation
• C) The multi-dose protocol is used because corticosteroid anti-inflammatory effects at mucosal surfaces are mediated by non-genomic membrane receptor signaling that saturates at low doses; repeated low-dose administration provides multiple cycles of membrane receptor activation without the receptor downregulation that occurs with a single high dose, maximizing the cumulative anti-edema effect
• D) The multi-dose protocol of methylprednisolone 20 mg every 4 hours for 4 doses maintains continuous glucocorticoid receptor occupancy and sustained transcriptional suppression of inflammatory mediators throughout the 12-hour pre-treatment window, ensuring that the genomic anti-inflammatory effect — which requires ongoing gene suppression to prevent ongoing cytokine and permeability mediator production — is sustained at the laryngeal mucosal level up to and including the moment of extubation; a single large dose given 12 hours before would produce peak genomic effects at 4 to 6 hours but allow mediator production to resume before extubation as the single-dose effect wanes
• E) The multi-dose protocol is required because methylprednisolone must achieve tissue concentrations above a minimum threshold in the laryngeal submucosal capillary endothelium that cannot be reached by a single 20 mg dose; the 4-dose schedule allows tissue accumulation of methylprednisolone in the lipophilic capillary endothelial membrane compartment to levels that a single dose cannot achieve, regardless of the dose size of that single administration

25. [CASE 7 — QUESTION 1] A 44-year-old man with no significant past medical history is admitted during influenza season with bilateral pneumonia and severe ARDS (acute respiratory distress syndrome) — PaO2/FiO2 (ratio of partial pressure of arterial oxygen to fraction of inspired oxygen) 78 mmHg on optimized ventilator settings. The precipitating etiology is unknown at admission. Based on DEXA-ARDS criteria, dexamethasone 20 mg IV daily is initiated on day 1. On day 2 at hour 36 of dexamethasone therapy, the respiratory viral panel returns positive for influenza A. The attending has not seen this situation before and asks what should be done and why. Which of the following best describes the correct action and its pharmacological rationale?

• A) Dexamethasone should be continued because the DEXA-ARDS trial enrolled all-cause ARDS regardless of etiology, including viral pneumonias, and withdrawing after 36 hours risks a rebound inflammatory surge from abrupt GR (glucocorticoid receptor) occupancy removal that will worsen oxygenation more than the theoretical viral replication risk
• B) Dexamethasone should be continued but the dose reduced to 6 mg IV daily — the dose used in the RECOVERY trial for COVID-19 — because this lower dose provides sufficient anti-inflammatory benefit at a level of immunosuppression that clinical evidence suggests is safe in influenza, balancing the inflammatory phase suppression against the viral replication risk
• C) Dexamethasone should be replaced with inhaled fluticasone delivered via the ventilator circuit, as inhaled corticosteroids suppress airway inflammatory mediators locally without producing the systemic T-cell suppression that impairs viral clearance; this route change preserves the anti-inflammatory benefit while eliminating the viral replication harm
• D) Dexamethasone should be continued because influenza-associated ARDS produces a cytokine storm identical to non-viral ARDS, and the corticosteroid harm in influenza is limited to prophylactic use in non-ARDS influenza pneumonia — once ARDS has developed, the inflammatory phase is the primary therapeutic target and viral replication is secondary
• E) Dexamethasone should be discontinued immediately because clinical and observational data associate corticosteroid use in influenza pneumonia with prolonged viral replication, increased viral shedding, and worse clinical outcomes — the immunosuppression that dampens the harmful inflammatory phase simultaneously impairs cytotoxic T lymphocyte activity and macrophage-mediated viral clearance needed to control active influenza replication; oseltamivir should be started promptly if not already prescribed

26. [CASE 7 — QUESTION 2] Continuing with the same patient. Dexamethasone is discontinued and oseltamivir is ordered. The patient is mechanically ventilated and cannot swallow. His serum creatinine is 1.1 mg/dL with an estimated GFR (glomerular filtration rate) of 78 mL/min/1.73m². The pharmacist is asked to confirm the correct antiviral agent, route of administration in a ventilated patient, and standard dosing for influenza ARDS. Which of the following correctly identifies oseltamivir's mechanism, route of administration in a ventilated patient unable to swallow, and dosing considerations?

• A) Oseltamivir acts by blocking the M2 ion channel in the influenza viral membrane, preventing viral uncoating and release of viral RNA into the host cell cytoplasm; in ventilated patients unable to swallow it should be administered by IV infusion because the oral/enteral route is unreliable; standard dosing is 150 mg IV twice daily, which must be reduced to 75 mg IV daily if creatinine clearance falls below 60 mL/min
• B) Oseltamivir is a neuraminidase inhibitor that prevents cleavage of sialic acid linkages on the host cell surface, trapping newly formed influenza virions at the cell surface and preventing their spread to adjacent cells; in ventilated patients it is administered via nasogastric or orogastric tube as the oral capsule formulation (opened and dissolved) or oral suspension, as enteral absorption is well maintained even in critically ill patients; standard dosing is 75 mg enterally twice daily for 5 days, with dose reduction required if creatinine clearance falls below 30 mL/min
• C) Oseltamivir is a neuraminidase inhibitor administered intravenously in all ICU patients; the oral formulation is not effective in mechanically ventilated patients because gastric dysmotility prevents absorption; standard IV dosing is 600 mg once daily for 10 days in severe influenza ARDS, with the dose doubled to 1200 mg daily in patients on extracorporeal membrane oxygenation (ECMO) due to drug sequestration in the circuit
• D) Oseltamivir blocks the influenza hemagglutinin receptor binding site on the viral surface, preventing attachment of influenza to sialic acid residues on respiratory epithelial cells and blocking new cell entry; in ventilated patients it is given via metered-dose inhaler through the ventilator circuit; standard inhaled dosing is 10 mg twice daily for 5 days for all levels of renal function because inhaled delivery bypasses systemic pharmacokinetics
• E) Oseltamivir acts by inhibiting influenza RNA-dependent RNA polymerase, preventing viral genome replication within the host cell nucleus; in ventilated patients it is given enterally via nasogastric tube as the standard 75 mg capsule formulation; standard dosing for ICU patients with severe influenza ARDS is 150 mg twice daily (double the standard dose) based on pharmacokinetic modeling showing reduced absorption in critically ill patients with inflammatory gut dysmotility

27. [CASE 7 — QUESTION 3] Continuing with the same patient. Oseltamivir is started enterally. Without dexamethasone, his PaO2/FiO2 remains at 78 mmHg on FiO2 0.85 with PEEP 14 cmH2O. The team asks what interventions with demonstrated mortality benefit or evidence-based oxygenation support are now available for this patient with influenza ARDS who cannot receive dexamethasone. Which of the following correctly identifies the hierarchy of interventions for severe ARDS when corticosteroids are contraindicated?

• A) The intervention with demonstrated mortality benefit in severe ARDS is prone positioning for at least 16 hours per day — the PROSEVA trial demonstrated a 28-day mortality reduction from 32.8 percent to 16.0 percent in patients with PaO2/FiO2 below 150 mmHg maintained for at least 16 consecutive hours per prone session; if oxygenation remains refractory despite prone positioning and optimized ventilator settings, inhaled nitric oxide (iNO) or inhaled epoprostenol can be used as rescue bridge therapy while ECMO evaluation is pursued — neither iNO nor inhaled epoprostenol reduces mortality but both can transiently improve PaO2/FiO2 as a bridge
• B) The primary mortality-reducing intervention when dexamethasone is contraindicated is immediate initiation of extracorporeal membrane oxygenation (ECMO); the CESAR and EOLIA trials both demonstrated that early ECMO for severe ARDS — defined as PaO2/FiO2 below 80 mmHg within the first 7 days — reduces 60-day mortality compared with conventional mechanical ventilation, and ECMO should not be delayed for prone positioning trials in patients with confirmed PaO2/FiO2 below 100 mmHg
• C) When dexamethasone is contraindicated in influenza ARDS, methylprednisolone 1 mg/kg/day should be substituted because methylprednisolone has lower systemic immunosuppressive effect than dexamethasone at equivalent anti-inflammatory doses, preserving more T-cell antiviral function while still suppressing the harmful inflammatory cascade; this is the standard alternative corticosteroid recommended in influenza ARDS management guidelines
• D) When dexamethasone is contraindicated, the only intervention with mortality benefit in severe ARDS is iNO; multiple randomized controlled trials confirm that iNO at 20 to 40 ppm reduces 28-day mortality by 15 to 20 percent in patients with PaO2/FiO2 below 100 mmHg, making it the primary escalation step for severe ARDS not eligible for corticosteroids
• E) When dexamethasone is contraindicated in influenza ARDS, high-dose IV vitamin C 1.5 g every 6 hours combined with thiamine 200 mg twice daily and hydrocortisone 50 mg every 6 hours constitutes the evidence-based HAT (Hydrocortisone, Ascorbic acid, Thiamine) protocol that reduces ARDS mortality to rates equivalent to dexamethasone through complementary antioxidant and anti-inflammatory mechanisms validated in the CITRIS-ALI and VITAMINS trials

28. [CASE 7 — QUESTION 4] Continuing with the same patient. After 5 days of oseltamivir and prone positioning, his respiratory viral panel on day 7 shows undetectable influenza A RNA. His PaO2/FiO2 has improved to 145 mmHg but he still meets moderate ARDS criteria and remains mechanically ventilated. The team asks whether dexamethasone can now be safely restarted given that viral replication has been eliminated, and what the mechanistic rationale for the timing decision should be. Which of the following best addresses this clinical question?

• A) Dexamethasone should be restarted immediately at the full DEXA-ARDS dose of 20 mg IV daily now that viral RNA is undetectable; the primary harm from corticosteroids in influenza ARDS was viral replication prolongation, and with viral RNA eliminated by oseltamivir, dexamethasone can be used without restriction; the inflammatory phase is still active as evidenced by PaO2/FiO2 of 145 mmHg and continued ventilator dependence
• B) Dexamethasone should not be restarted under any circumstances once influenza has been confirmed; the FDA label for dexamethasone in ARDS explicitly contraindicates its use after influenza diagnosis regardless of viral clearance status, and re-initiation after prior contraindicated use creates medicolegal liability
• C) Dexamethasone can be restarted only after the patient has been successfully extubated; corticosteroids improve oxygenation in ARDS but accelerate respiratory muscle atrophy when given to ventilated patients, so restraining corticosteroid use to the post-extubation period avoids ICUAW while still providing the anti-inflammatory benefit needed to prevent post-extubation inflammatory relapse
• D) The decision to restart dexamethasone after influenza viral clearance requires weighing the DEXA-ARDS inflammatory phase benefit against the risk that some viral clearance mechanisms remain active beyond the point of undetectable RNA; reasonable clinical practice is to consider restarting dexamethasone if the patient still meets moderate-to-severe ARDS criteria (PaO2/FiO2 at or below 200 mmHg) on day 7 or beyond with confirmed viral clearance — the inflammatory phase is the target — while recognizing that this specific scenario lacks individual trial evidence and represents extrapolation from the DEXA-ARDS and influenza-harm datasets
• E) Dexamethasone should never be restarted in influenza ARDS regardless of viral clearance because the structural lung injury from influenza ARDS is exclusively fibroproliferative by day 7, and corticosteroids are harmful in the fibroproliferative phase across all ARDS etiologies — the only appropriate management at day 7 is supportive care and physical rehabilitation without any pharmacological anti-inflammatory intervention